Camacho OA, Acosta BGR, Rositas NFH, Canizález OJL

Language: Spanish
References: 15
Page: 44-48
PDF size: 1156.25 Kb.

ABSTRACT

Introduction. Pseudomonas aeruginosa is an organism with nosocomial prevalence and is a common cause of infection in hospitalized patients. The understanding of the epidemiology of P. aeruginosa in hospitalization wards may favor a better control of infections caused by this agent.
Materials and Methods. Retrospective and descriptive study. We evaluated the positive cultures reported in a teaching hospital over a period of three years. We analyzed demographic and microbiologic variables.
Results. A total of 1,254 cultures were reported. Forty-three were eliminated and 1,211 were analyzed. Main culture samples were P. aeruginosa was isolated were urine, wound secretions and tracheal aspirates. The hospital areas with more positive cultures were the medical and surgical intensive care units with 21.7%.
Antimicrobial resistance had an uprise between 2004 and 2005 with a subsequent downfall between 2005 and 2006; this was true with respect to all antibiotics tested except gentamicine and ticarcilline/clavulanate. The lowest percentage of resistance throughout the study was obtained by imipenem with 23, 31 and 28.5% respectably. The highest percentage of resistance was reported for ticarcillin/clavulanate, gentamicin, amikacin, ciprofloxacin, ceftazidime y piperacillin/tazobactam.
Discussion. The results of the present study show isolates with higher percentage of resistance for amikacin, gentamicin, ceftazidime, imipenem, cefepime, piperacillin/tazobactam, ciprofloxacin and ticarcillin/clavulanate in comparison with the national mean reported.
Conclusion. The isolates analyzed in the present study pose more resistance to antimicrobials than expected. The effects of judicious use of antimicrobials favors the lowering of resistance rate.

REFERENCES

1. Mandell GL, Dolin R, Bennett JE. Enfermedades infecciosas, principios y práctica. Elsevier 2006; 6a ed.: 2587.

2. St Georgiev, Vassil. Infectious diseases in immunocompromised host. Estados Unidos, CRC Press, 1998: 501-503.

3. Osmon S, Ward S, Fraser V et al. Hospital mortality for patients with bacteremia Due to Staphylococcus aureus or Pseudomonas aeruginosa. CHEST 2004; 125: 607-616.

4. Fagon J, Chastre J. Antimicrobial Treatment for Hospital- Aquired Pneumonia. Clin Chest Med 2005; 26; 97-104.

5. Wolfgang M, Kulasekara B, Liang X et al. Conservation of genome centent and virulence determinants among clinical and enviromental isolates of Pseudomonas aeruginosa. PNAS 2003; 14: 8484-8489.

6. Weingarten JA, Paterson DL, Yu VL. Pneumonia caused by Pseudomonas aeruginosa. Cur Treat Opt in Infec Dis 2003; 5: 159-169.

7. Garau J, Gomez L. Pseudomonas aeruginosa pneumonia. Current Opinion in Infectious Diseases 2003; 16: 135-143.

8. Wikler MA, Cockerill FR, Craig WA et al. Performance standards for antimicrobial susceptibility testing; fiftheenth informational supplement. Clinical and Laboratory Standards Institute 2005; 25: 108.

9. Bouza E,Garcia-Garrote F, Cercenado E et al. Pseudomonas aeruginosa: A survey of resistance in 136 hospitals in Spain. Antimicrob Agents Chemother, 1999; 33: 981-982.

10. Blandino G, Marchese A, Ardito F et al. Antimicrobial susceptibility profiles of Pseudomonas aeruginosa and Staphylococcus aureus isolated in Italy from patients with hospital acquired-infections. International Journal of Antimicrobial Agents 2004; 24: 515-518.

11. Donís-Hernández J, Tinoco J, Sifuentes-Osornio J y cols. Tendencia de la resistencia bacteriana en bacilos gram negativos de 1998 a 2002: Programa de resistencia bacteriana en México (Cartel). Congreso Internacional de Enfermedades Infecciosas 2004 Cancún, México.

12. Donís-Hernández J, Tinoco J, Sifuentes-Osornio J y cols. Tendencia de la resistencia en Pseudomonas aeruginosa y Acinetobacter spp aisladas de secreción bronquial. Programa de resistencia bacteriana en México. Enfermedades Infecciosas y Microbiología 2003; 3: 78.

13. Henwood C, Livermore D, James D et al. Antimicrobial susceptibility of Pseudomonas aeruginosa: result of a UK survey and evaluation of the British Society of Antimicrobial Chemotherapy disc susceptibility test. Journal of Antimic Chemo 2001; 47: 789-799.

14. Joyce M, Woods CW. Antibacterial susceptibility testing in clinical laboratory. Infect Dis Clin N Am 2004; 18: 401-434.

15. Burns JL, Saiman L, Whittier S. Comparison of Agar Diffusion Methodologies for Antimicrobial. J. Clin. Microbiol 2000; 38: 1818-1822.